机构:[1]Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, PR China四川大学华西医院
Two of the biggest hurdles in the deployment of chemotherapeutics against glioma is a poor drug concentration at the tumor site and serious side effects to normal tissues. Nanocarriers delivering different drugs are considered to be one of the most promising alternatives. In this study, a dual delivery system (methoxy poly(ethylene glycol)-poly(ε-caprolactone) (MPEG-PCL)) loaded with α-mangostin (α-m) and doxorubicin (Dox) was decorated and constructed by self-assembly to determine its ability to treat glioma. Molecular dynamics simulations showed that MPEG-PCL could provide ideal interaction positions for both α-m and Dox, indicating that the two drugs could be loaded into MPEG-PCL. Based on the in vitro results, MPEG-PCL loaded with α-m and Dox (α-m-Dox/M) with a size of 25.68 nm and a potential of -1.51 mV was demonstrated to significantly inhibit the growth and promote apoptosis in Gl261, C6 and U87 cells, and the effects of the combination were better than each compound alone. The mechanisms involved in the suppression of glioma cell growth were blockage of the cell cycle in S phase by inhibition of CDK2/cyclin E1 and promotion of apoptosis through the Bcl-2/Bax pathway. The synergetic effects of α-m-Dox/M effectively inhibited tumor growth and prolonged survival time without toxicity in mouse glioma models by inducing glioma apoptosis, inhibiting glioma proliferation and limiting tumor angiogenesis. In conclusion, a codelivery system was synthesized to deliver α-m and Dox to the glioma, thereby suppressing the development of glioma by the mechanisms of cell cycle arrest and cellular apoptosis, which demonstrated the potential of this system to improve the chemotherapy response of glioma.
基金:
Sichuan Science and Technology Program (No.
2019YFS0089 and 2020YFS0217), the Ministry of Science and Technology of
the People’s Republic of China (No. 2018ZX09201018-005), the full-time
postdoctoral research and development fund of Sichuan University (No.
20826041D4048), and the full-time postdoctoral research and development
fund of West China Hospital of Sichuan University (No. 2020HXBH059).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|2 区生物学
小类|2 区细胞生物学
最新[2023]版:
大类|1 区生物学
小类|2 区细胞生物学
第一作者:
第一作者机构:[1]Department of Neurosurgery and Institute of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, PR China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Nie Wen,Zan Xin,Yu Ting,et al.Synergetic therapy of glioma mediated by a dual delivery system loading α-mangostin and doxorubicin through cell cycle arrest and apoptotic pathways.[J].Cell death & disease.2020,11(10):928.doi:10.1038/s41419-020-03133-1.
APA:
Nie Wen,Zan Xin,Yu Ting,Ran Mengni,Hong Zehua...&Gao Xiang.(2020).Synergetic therapy of glioma mediated by a dual delivery system loading α-mangostin and doxorubicin through cell cycle arrest and apoptotic pathways..Cell death & disease,11,(10)
MLA:
Nie Wen,et al."Synergetic therapy of glioma mediated by a dual delivery system loading α-mangostin and doxorubicin through cell cycle arrest and apoptotic pathways.".Cell death & disease 11..10(2020):928